DaVita Inc. $DVA Stock: ProShare Advisors LLC Raises Holdings

ProShare Advisors LLC raised its holdings in DaVita Inc. (NYSE:DVA) by 99.3% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,161 shares of the company’s stock after buying an additional 6,558 shares during the period. ProShare Advisors LLC’s holdings in DaVita were worth $2,302,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. Vise Technologies Inc. boosted its holdings in shares of DaVita by 16.5% during the 3rd quarter. Vise Technologies Inc. now owns 2,867 shares of the company’s stock worth $502,000 after buying an additional 405 shares during the period. State of Wyoming acquired a new stake in DaVita during the third quarter worth approximately $519,000. Parcion Private Wealth LLC bought a new stake in shares of DaVita during the third quarter worth approximately $226,000. Asset Management One Co. Ltd. grew its position in shares of DaVita by 28.0% in the third quarter. Asset Management One Co. Ltd. now owns 1,675 shares of the company’s stock valued at $293,000 after purchasing an additional 366 shares during the last quarter. Finally, Viewpoint Investment Partners Corp grew its position in shares of DaVita by 21.4% in the third quarter. Viewpoint Investment Partners Corp now owns 1,700 shares of the company’s stock valued at $297,000 after purchasing an additional 300 shares during the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on DVA shares. Barclays dropped their target price on DaVita from $224.00 to $216.00 and set an “equal weight” rating for the company in a report on Monday, November 2nd. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $265.00 target price on shares of DaVita in a research report on Wednesday, August 5th. TD Cowen raised their target price on shares of DaVita from $220.00 to $228.00 and gave the stock a “buy” rating in a report on Monday, November 2nd. Oppenheimer set a $220.00 price target on shares of DaVita in a research report on Friday, August 7th. Finally, Weiss Ratings upgraded DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, October 9th. Four investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $235.86.

DaVita Stock Down 1.8%

Shares of NYSE DVA traded down $3.55 during midday trading on Friday, reaching $191.27. 603,670 shares of the company were exchanged, compared to its average volume of 796,165. The stock’s 50-day moving average price is $182.52 and its 200-day moving average price is $178.61. The stock has a market cap of $12.03 billion, a P/E ratio of 14.08, a PEG ratio of 0.47 and a beta of 0.87. DaVita Inc. has a one year low of $101.00 and a one year high of $247.49.

DaVita (NYSE:DVA) last posted its earnings results on Thursday, October 29th. The company reported $3.82 EPS for the quarter, beating the consensus estimate of $3.57 by $0.25. DaVita had a negative return on equity of 225.93% and a net margin of 6.49%. The firm had revenue of $3.58 billion during the quarter, compared to the consensus estimate of $3.52 billion. During the same period last year, the company earned $2.51 earnings per share. The business’s quarterly revenue was up 4.6% on a year-over-year basis. On average, equities research analysts anticipate that DaVita Inc. will post 14.66 EPS for the current year.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.